FINANCIALS

Breast Cancer Trials (BCT) is investing more into our research program than ever before. That means more lives saved and better treatments sooner.

BCT generated gross fundraising income of $5.432m for the year, which is an increase of $0.146m from the prior year.

The Total Expenditure and the net Deficit from Direct Research activities for the year were $8.335m and $3.109m respectively. The Total Expenditure was a 12% increase over the prior year.

BCT recorded an operating deficit for the year ended 31 March 2023 of $2.866m. There was operating income of $11.217m and operating expenses of $14.083m.

After Investment losses during the year of $1.662m (due to movements in Australian and international markets) there was a reported Net Deficit of $4.528m.

It is forecast that BCT will need reserves of $17.711m (net of external cost recoveries) to meet the committed expenses of its approved Research Program.